Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021

Spectral Medical Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments

Spectral Medical Announces U.S. FDA Approval of Tigris Trial Protocol Amendment to Expand Inclusion Criteria 

Amendment aligns eligibility for Tigris with current clinical practice in septic shock

Potential to improve Tigris enrollment rates by 25% to 50% and reduce time to trial completion

Five additional clinical sites now participating with 15 total sites fully on board

Spectral Announces Third Quarter Results and Provides Corporate Update

Reports early patient mortality data in Tigris Trial on target with expectations

Spectral to Present at the Benzinga Global Small Cap Conference on October 27, 2021

Spectral and Dialco announce Dr. John Kellum to be featured AS Keynote Lecturer at the 39th Vicenza Course on AKI and CRRT

Dr. Kellum Invited to Participate on Additional Featured Panels

Spectral Medical’s CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day and Sepsis Awareness Month

Spectral Sponsors Live Webinar hosted by its CMO at the Sepsis Alliance Symposium

September 13th is World Sepsis Day; September is designated as Sepsis Awareness Month

Spectral Medical Announces its Participation at Upcoming Investor Conferences  

Spectral Announces Second Quarter Results and Provides Corporate Update

Spectral Medical Announces Internal Reorganization of its Wholly Owned Subsidiary
Dialco Medical to Enhance Operations and Accelerate Commercialization

Outlines anticipated milestones related to its DIMI and SAMI devices

Spectral Medical Inc. Provides Tigris Clinical Trial Update

• Recruitment activity returning to normalized levels with 12 trial sites actively screening patients
• 15 sites on track to open for enrollment by the end of Q3 2021

Spectral Medical Inc. Closes $10 Million Offering of Units

Spectral Medical Inc. Announces $10 Million Offering

Spectral Medical Inc. Announces Overnight Marketed Offering

Spectral Announces First Quarter Results and Provides Corporate Update

• Immediately enables DIMI to be used within Canadian hospitals, clinics and in home

Dr. Paul Walker will remain on the Board of Directors focusing on the seamless transition of management and on ensuring continuity of the Tigris Trial

A World Authority in Blood Purification and Renal Replacement Therapy

• MDSAP is the highest quality and regulatory standard in the medical device industry

• Dialco’s DIMI receives FDA 510(k) clearance for use in hospital and clinical settings – a significant step in the full regulatory development of DIMI
• Tigris trial sites increased to eleven, with additional sites identified
• Company to host Virtual Investor Day on December 4th, 2020

• Operating the SAMI viewed as both simple and safe by the nurses
• Successful remote deployment of SAMI with only 3 hours of virtual training

• Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
• U.S. skilled nursing facilities market represents an estimated US$2 billion market annually 

Protocol Amendment allows for increase in TIGRIS sites to 15 while potentially accelerating patient enrolling and offsetting any COVID-19 pandemic-related delays

• Early Tigris trial observations in-line with Euphrates post-hoc results
• Investigator-driven studies show endotoxin levels significantly elevated in most patients with COVID-induced septic shock
• Q4 2020 EAA multi-country European launch
• DIMI traditional FDA 510(k) approval for in hospital use expected in Q3 2020

• Adds significant experience and strength to the Company’s commercialization focus >

• The Company remains well positioned with financial strength
• COVID-19 patients using PMX in the U.S. showing positive signs in recovery
• SAMI used successfully for CRRT in COVID-19 patients >

• • PMX has successfully been used for treatment in COVID-19 patients in the U.S., Japan and Italy 
  • Interim Order expands already approved PMX Health Canada indications for use to include treatment of COVID-19 patients >

• PMX has successfully been used for treatment in COVID-19 patients in the U.S., Japan and Italy
• IDE approval provides access to PMX to help clinicians treat COVID-19 patients in septic shock
• Publications have demonstrated endotoxin removal by PMX can decrease cytokine storm and dependency on ventilators >

Two new hospitals in Canada and the U.S. place orders for SAMI >